Ohr Pharmaceutical 8-K


Exhibit 10.41




SUBSCRIPTION
AGREEMENT






This SUBSCRIPTION
AGREEMENT (this “Agreement”) is dated as of April 8, 2014, between Ohr Pharmaceutical, Inc., a Delaware corporation
(the “Company”), and the purchaser identified on the signature page hereto (the “Purchaser”).


WHEREAS, the Purchaser
desires to subscribe for, and the Company desires to issue, shares of the Company’s common stock, $0.0001 par value per share
(the “Common Stock”), to the Purchaser pursuant to the terms and conditions of this Agreement;


NOW, THEREFORE,
upon the execution and delivery of this Agreement, the Company and the Purchaser agree as follows:


1.                 
Subscription. The Purchaser, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase
the number of shares of Common Stock (the “Shares”) at the per share purchase price and aggregate purchase price
(the “Purchase Price”) as set forth on the signature page hereto, and the Company, intending to be legally bound,
hereby agrees to issue and sell the Shares to the Purchaser, provided, however, that the Company reserves the right
to accept or reject this subscription for Shares, in whole or in part. If the Company elects to accept this subscription for Shares
in part, it shall promptly notify the Purchaser by delivery to the Purchaser by email of the signature page countersigned by the
Company and reflecting the amount of the subscription accepted.


2.                 
Registration of Shares. The offering and sale of the Shares (the “Offering”) are being made pursuant
to (a) an effective Registration Statement on Form S-3 (File No. 333-193434) (the “Registration Statement”)
filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act
of 1933, as amended (the “Securities Act”), including the prospectus contained therein (the “Base Prospectus”),
which relates, among other things, to the Shares and the sale thereof from time to time in accordance with Rule 415 under
the Securities Act, and (b) a prospectus supplement (the “Prospectus Supplement” and, together with the
Base Prospectus, the “Prospectus”) containing certain supplemental information regarding the Shares and terms
of the Offering that will be filed with the Commission and delivered to the Purchaser (or made available to the Purchaser by the
filing by the Company of an electronic version thereof with the Commission) no later than the second business day following the
date of this Agreement.


3.                 
Purchase and Sale of Shares. The Company agrees to issue and sell to the Purchaser and the Purchaser agrees to purchase
the Shares at a closing to take place at the offices of the Company, or such other place as the Purchaser and the Company shall
mutually agree, including by way of the exchange of facsimile or “pdf” copies of signatures (the “Closing”),
no later than the third Trading Day (as such term is defined below) following the date hereof (the “Closing Date”). 
At the Closing, the Company shall deliver instructions to the Company’s transfer agent to issue the Shares as of the Closing
Date and deliver via the Depository Trust Company Deposit Withdrawal Agent Commission System (“DWAC”) the Shares,
registered in the name of the Purchaser, against delivery of the




    	1



    	 



    

Purchase Price, which shall be paid
by the Purchaser at the Closing by wire transfer of immediately available funds to the escrow account set forth on Schedule
I hereto (“Escrow Account”). The term “Trading Day” means a day on which the principal
NASDAQ Stock Market is open for trading.


Prior to Closing,
the Purchaser shall direct the broker-dealer at which the account or accounts to be credited with the Shares being purchased by
the Purchaser are maintained, which broker/dealer shall be a DTC participant, to set up a DWAC instructing the Company’s
transfer agent, to credit such account or accounts with the Shares by means of an electronic book-entry delivery. Simultaneously
with the delivery to the designated escrow agent by the Purchaser of the Purchase Price at Closing, the Company shall direct its
transfer agent to credit the Purchaser’s account or accounts with the Shares pursuant to the information contained in the
DWAC (as specified by the Purchaser on the Investor Questionnaire annexed hereto as Exhibit A).


4.                 
Closing Conditions.


(a)              
The obligations of the Company hereunder are subject to the following conditions being met:


(i)                
the accuracy in all material respects as of the date hereof of the representations and warranties by the Purchaser contained
herein; and


(ii)             
the delivery by the Purchaser of the Purchase Price to the Escrow Account for the Shares as set forth herein on the Closing
Date.


(b)              
The obligations of the Purchaser hereunder are subject to the following conditions being met:


(i)                
the accuracy in all material respects as of the date hereof of the representations and warranties by the Company contained
herein;


(ii)             
the delivery by the Company to the Purchaser of the Prospectus and Prospectus Supplement (which may be delivered in accordance
with Rule 172 under the Securities Act); and


(iii)           
the delivery by the Company to the Purchaser of a copy of the irrevocable instructions to the Company’s transfer agent
instructing the transfer agent to deliver on an expedited basis via DWAC the number of Shares subscribed for that was accepted
by the Company, registered in the name of the Purchaser.


5.                 
Representations and Warranties of the Company.  As of the date hereof, the Company hereby represents and warrants
to the Purchaser that:


(a)              
Organization. The Company is a corporation, duly organized, validly existing and in good standing under the laws
of the State of Delaware.




    	2



    	 



    

(b)              
 Authority and Validity. The Company has all requisite corporate power and authority to execute, deliver and perform
its obligations under this Agreement and to consummate the transactions contemplated hereby.  The execution, delivery and
performance by the Company of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly
authorized by all necessary action required on the part of the Company, and no other proceedings on the part of the Company are
necessary to authorize this Agreement or for the Company to perform its obligations under this Agreement.  This Agreement
constitutes the lawful, valid and legally binding obligation of the Company, enforceable in accordance with its terms, except as
the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement
of creditors’ rights generally and general equitable principles regardless of whether such enforceability is considered in
a proceeding at law or in equity.


(c)               
Valid Issuance of Common Stock; Registration. The Shares, when issued, sold and delivered in accordance with the
terms hereof for the Purchase Price, will be duly and validly authorized and issued, fully paid and nonassessable and free of restrictions
on transfer other than the applicable state and federal securities laws. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, including the Prospectus, and such amendments and supplements thereto
as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no
stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the
Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. At the time the Registration Statement and any amendments thereto became effective,
at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading.


(d)              
Registration Statement. The Registration Statement is in full force and effect and no cease and desist order or other
suspension of the Registration Statement exists, has been imposed or, to the knowledge of the Company is threatened by the Commission.


(e)               
No Violation or Conflict. The execution, delivery and performance of this Agreement and the transactions contemplated
hereby do not (i) violate, conflict with or result in the breach of any provision of the Company’s Certificate of Incorporation
or Bylaws, (ii) conflict with or violate any law, rule, regulation, order, judgment or decree applicable the Company or any
of its assets, properties or businesses, or (iii) conflict with, result in any breach of, constitute a default (or event that
with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others




    	3



    	 



    

any rights of termination, amendment,
acceleration, suspension, revocation or cancellation of, or result in the creation of any encumbrance on any of the assets or properties
of the Company, pursuant to any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise
or other instrument or arrangement to which the Company is a party except, in the case of clauses (ii) and (iii), to the extent
that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably be expected to
have a material adverse effect on the Company. No third party has a right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the hereunder. Except as a result of the purchase and sale
of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any
third party any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements
by which the Company or any subsidiary is or may become bound to issue additional shares of Common Stock or equivalents thereof.
The issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any third
person and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset
price under any of such securities.


(f)                
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial
statements included within the reports filed with the Commission, except as specifically disclosed in such reports filed prior
to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to
result in (i) a material adverse effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely
basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”)
, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not
altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)
the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Shares contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its subsidiaries or their respective
businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is made or




    	4



    	 



    

deemed made that has not been publicly
disclosed at least 1 day prior to the date that this representation is made.


(g)              
Listing and Maintenance Requirements. Except as set forth in the documents incorporated in the Prospectus Supplement,
the Company has not, in the 12 months preceding the date hereof, received notice from any trading market on which the Common Stock
is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such trading market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be,
in compliance with all such listing and maintenance requirements.


(h)              
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement,
the Company confirms that neither it nor any third party acting on its behalf has provided the undersigned or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement.


(i)                
Regulation M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken,
directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement
Agent in connection with the placement of the Shares.


(j)                
Governmental/Regulatory Consents and Approvals. Except for filings under federal securities laws and, if required,
NASDAQ Stock Market rules and regulations, the execution, delivery and performance of this Agreement by the Company do not, and
the consummation of the transactions contemplated hereby do not and will not, require any permits, consents, approvals, orders,
authorizations of, or declarations to or filings with any federal, state, local or foreign government or regulatory authority,
which has not already been obtained, effected or provided.


6.                 
Representations, Warranties and Covenants of the Purchaser.  As of the date hereof, the Purchaser hereby represents
and warrants to the Company that:


(a)              
The Purchaser has received (or otherwise had made available to him by the filing by the Company of an electronic version
thereof with the Commission) the Base Prospectus which is a part of the Registration Statement, and the documents incorporated
by reference therein (collectively, the “Disclosure Package”), prior to or in connection with the execution
of this Agreement. The Purchaser acknowledges that, prior to the delivery of this Agreement to the Company, the Purchaser will
receive certain additional information regarding the Offering, including pricing information (the “Offering Information”).
Such information may be provided to the Purchaser by any means permitted under the Act, including the Prospectus Supplement, a
free writing prospectus and oral communications.




    	5



    	 



    

(b)              
 At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is, an “accredited investor”
as defined in Rule 501. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Shares and, at the present time, is able to afford a complete loss of such investment. The Purchaser acknowledges
that it has had the opportunity to review this Agreement and the Disclosure Package and has been afforded (i) the opportunity to
ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms
and conditions of the offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. 
The Purchaser acknowledges and agrees that neither the Placement Agents nor any Affiliate of the Placement Agents has provided
the Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. 
Neither the Placement Agents nor any affiliate of the Placement Agents has made or makes any representation as to the Company or
the quality of the Shares and the Placement Agents and any affiliates of the Placement Agents may have acquired non-public information
with respect to the Company which the Purchaser agrees need not be provided to it.  In connection with the issuance of the
Shares to the Purchaser, neither the Placement Agents nor any of the Placement Agents’ affiliates has acted as a financial
advisor or fiduciary to the Purchaser.


(c)               
The Purchaser understands that nothing in this Agreement, the Disclosure Package or any other materials presented to the
Purchaser in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice.  The Purchaser
has consulted such legal, tax and investment advisors and made such investigations as he, it his sole discretion, has deemed necessary
or appropriate in connection with his purchase of the Shares.


(d)              
No person or entity acting on behalf of, or under the authority of, the Purchaser is or will be entitled to any broker’s,
finder’s, or similar fees or commission payable by the Company.


(e)               
Since the date that the Purchaser became aware of the proposed Offering, the Purchaser has not disclosed any information
regarding the Offering to any third parties (other than its legal, accounting and other advisors) and has not engaged in any purchases
or sales of the securities of the Company involving the Company’s securities.


(f)                
No offer by the Purchaser to buy the Shares will be accepted and no part of the Purchase Price will be delivered to the
Company until the Purchaser has received the Offering Information and the Company has accepted such offer by countersigning a copy
of this Agreement, and any such offer may be withdrawn or revoked, without




    	6



    	 



    

obligation or commitment of any kind,
at any time prior to the Company sending (orally, in writing or by electronic mail) notice of its acceptance of such offer. An
indication of interest will involve no obligation or commitment of any kind until the Purchaser has been delivered the Offering
Information and this Agreement is accepted and countersigned by or on behalf of the Company. The Purchaser understands and agrees
that the Company, in its sole discretion, reserves the right to accept or reject this subscription for Shares, in whole or in part.


7.Public
Announcement. The Company and the Purchaser agree that the Company shall, prior to the opening of the financial markets in
New York City on the business day immediately after the date hereof: (a) issue a press release announcing the Offering and disclosing
all material information regarding the Offering and (b) file a Current Report on Form 8-K with the Securities and Exchange Commission,
including a form of this Agreement as an exhibit thereto, which discloses all material non-public information disclosed to the
Purchaser. Following such public announcement, the Company covenants and agrees that neither it, nor any other Person acting on
its behalf will provide the Purchaser or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto the Purchaser shall have entered into a written agreement with the Company regarding
the confidentiality and use of such information. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement
to the contrary, the Company expressly acknowledges and agrees that (i) the Purchaser makes no representation, warranty or covenant
that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated
by this Agreement are first publicly announced hereunder, (ii) the Purchaser shall not be restricted or prohibited from effecting
any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release hereunder and (iii)
the Purchaser shall not have any duty of confidentiality to the Company or its Subsidiaries after the issuance of the initial press
release hereunder. 


8.Listing
of Common Stock. The Company hereby agrees to use its reasonable best efforts to maintain the listing or quotation of the Common
Stock on the trading market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list
or quote all of the Shares on such trading market and promptly secure the listing of all of the Shares on such trading market.


9.Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or




    	7



    	 



    

in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action, suit or proceeding shall
be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT
BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE
LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.


10.Entire
Agreement. This Agreement constitutes the entire agreement between the Company and the Purchaser with respect to the matters
covered hereby and supersedes all prior agreements and understanding with respect to such matters between the Company and the Purchaser.


11.Severability.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality
and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.


12.Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.


13.Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is
required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.


14Third-Party
Beneficiaries. The Placement Agents shall be third party beneficiaries of the representations and warranties of the Company
and the Purchaser.




    	8



    	 



    

15.Counterparts;
Facsimile or “pdf” Copies.  This Agreement may be executed in counterparts, each of which, when executed,
shall be deemed an original but all of which, taken together, shall constitute one and the same Agreement.  Delivery of an
executed copy of a signature page to this Agreement by facsimile or “pdf” transmission shall be as effective as
delivery of a manually executed copy of this Agreement and shall be as effective and enforceable as the original.


[SIGNATURES
FOLLOW ON NEXT PAGE]




    	9



    	 



    

 


IN WITNESS WHEREOF,
the undersigned has caused this Agreement to be duly executed by its authorized signatory as of the date first indicated above.


	 	 
	 	PURCHASER:
	 	 
	Subscription Amount: $_________________	_____________________________________
	 	[Name of Purchaser]
	Purchase Price per Share: $_______________	 
	 	 
	No. of Shares: ________________________	By:___________________________________
	Subscription Amount: $_________________	Name:
	 	Title:
	 	 
	 	 
	 	 
	 	OHR PHARMACEUTICAL, INC.
	Agreed and Accepted this	 
	________ day of April, 2014:	 
	 	By:___________________________________
	 	Name:
	 	Title:
	 	 
	 	Address for Notice:
	 	 
	Subscription Amount Accepted:	800 Third Avenue, 11th Floor
	$_________________	New York, New York 10022
	 	Telephone:(212) 682 8452
	No. of Shares Accepted:	Facsimile: (212) 644-0544
	__________________	E-mail: sam@ohrpharmaceutical.com
	 	Attention: Chief Financial Officer
	 	 
	 	With a copy to:
	 	 
	 	Hahn & Hessen LLP
	 	488 Madison Avenue
	 	New York, New York 10022
	 	Telephone: (212) 478-7200
	 	Facsimile: (212) 478-7400
	 	E-mail: jkardon@hahnhessen.com
	 	Attention: James Kardon, Esq.


 




    	10



    	 



    

EXHIBIT
A


INVESTOR
QUESTIONNAIRE


	1.	The exact name that your Shares are to be registered in. You may use a nominee name if appropriate:
	 	 
	 	 



 


	2.	The relationship between the Purchaser and the registered holder listed in response to item 1 above:
	 	 
	 	 



	3.	The mailing address of the registered holder listed in response to item 1 above:
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	Fax:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 



	4.	The Social Security Number or Tax Identification Number of the registered holder listed in the
response to item 1 above:
	 	 
	 	 



	5.	Name
of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained):

	 	 
	 	 



	6.	DTC Participant Number:
	 	 
	 	 



	7.	Name
of Account at DTC Participant being credited with the Shares:

	 	 
	 	 



	8.	Account Number at DTC Participant being credited with the Shares: